DCISionRT is a novel molecular test that assesses the 10-year risk of recurrence after Breast Conserving Surgery (BCS) and the benefit of treating with radiation therapy (RT) for women with Ductal Carcinoma In Situ (DCIS).
DCIS is a pre-invasive disease of the breast that may lead to invasive breast cancer, if not treated.¹ After breast conserving surgery (BCS) for DCIS, radiation therapy is often used to minimise the risk of recurrence.
Interim results from the AUS-PREDICT registry demonstrate a 45% change in radiation therapy recommendations when using the DCISionRT test² which shows promise in preventing the over-treatment and under-treatment of Australian women with DCIS.
GenesisCare, a leading provider of integrated cancer care, in partnership with Prelude Corporation (PreludeDXTM), a leader in molecular diagnostics and precision medicine, formed a strategic partnership in 2021 to bring DCISionRT to Australia for the first time. They established the AUS-PREDICT registry to collect real-world data, to further the development of precision medicine and decision tools globally.
The interim analysis studied 232 patients from Australia who had received the DCISionRT test following BCS. Radiation therapy recommendation decreased by 70% in patients with a low risk DCISionRT score and increased by 29% in patients with elevated risk scores.²
Historically, clinical pathology, such as tumour grade and size, were used to make decisions regarding treatment plans for patients with DCIS. Leading Specialist Breast Surgeon and Director of Breast Cancer Services for Royal Melbourne and Royal Women’s Hospital, Melbourne, Professor Bruce Mann, said: “This data demonstrates the integration of DCISionRT into clinical decision making has a substantial impact on RT recommendations, and has the ability to prevent over, and under-treatment of DCIS patients.”
The study highlights that DCISionRT is a promising, predictive tool, arming clinicians and patients with necessary information to enable informed decisions about treatment options, based on an individual’s biological risk profile.
Principal Investigator and GenesisCare Radiation Oncologist, Dr Yvonne Zissiadis, said the interim results “demonstrate the critical role of DCISionRT in the clinical treatment pathway for DCIS patients, ensuring women receive the right treatment, at the right time.”
The analysis was performed on the first 232 patients treated at 50 sites across Australia who had definitive BCS and subsequent DCISionRT testing. The median age of patients was 63 years, nuclear grade was high in 52%, and tumor size was 2.5cm or greater for 16% of the cohort.
Test results were DS Low Risk (DS ≤ 3) for 65% of women and 35% were DS Elevated Risk (DS > 3). Notably, RT recommendation decreased by 70% in DS Low Risk patients, but increased 29% in DS Elevated Risk patients.²
The first interim analysis of AUS-PREDICT is highly consistent with the US-PREDICT registry, that has completed 2,500 patient enrolments.³
Troy Bremer, PhD, Chief Scientific Officer of PreludeDx, Laguna Hills, California, US, said “In the registry studies in both countries, DCISionRT was the most impactful single factor for changing treatment recommendations regarding radiation therapy following breast conserving surgery.”
These results highlight the significance of including DCISionRT in the clinical decision-making pathway regarding the use of RT in patients living with DCIS, following BCS.
References:
- Breast Cancer Network Australia. Understanding breast cancer: Ductal Carcinoma In Situ. 2022 [cited October 2022]; Available online here.
- Zissiadis et al., Interim Analysis of the PREDICT Registry Australia: Changes in Treatment Recommendation for a Biologic Signature Predictive of Radiation Therapy (RT) Benefit in Patients with DCIS [abstract], in Australasian International Breast Congress. 2022: Brisbane, Australia.
- Shah et al., The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery. Ann Surg Oncol 2021. 28: pp. 5974–5984.
Source: Sponsored by GenesisCare. For more information, view GenesisCare’s Company Bio page.